Bristol Myers Squibb entered two separate research collaboration and licensing deals, one with San Francisco-based SyntheX and the second with London’s Autolus Therapeutics.
Evotec SE is on a deal-making spree. The company just inked another contract, this time with Janssen Pharmaceutical that showcases Evotec’s end-to-end integrated drug discovery and development platform.
Protein degradation continues to be a hot area of interest for companies. Weeks after Bristol-Myers Squibb and Evotec forged a $5 billion collaboration expansion to develop molecular glue degraders, Merck KGaA and Austria’s Proxygen have struck a similar deal valued at $554 million.